Acromegaly
By deep intramuscular injection using depot injection, initially 20mg every 4 weeks for 3 months then adjusted according to response, increased if necessary up to 30mg every 4 weeks, to be administered into the gluteal muscle.
By deep intramuscular injection using depot injection, initially 20mg every 4 weeks for 3 months then adjusted according to response, increased if necessary up to 30mg every 4 weeks, to be administered into the gluteal muscle.
By deep intramuscular injection using depot injection, initially 20mg every 4 weeks for 3 months then adjusted according to response, increased if necessary up to 30mg every 4 weeks, to be administered into the gluteal muscle.
Refer to product literature.
Refer to product literature.
Refer to product literature.
Prescribe as the IPSEN brand
Initially 60mg every 28 days, adjusted according to response; maximum dose 120mg every 28 days by deep subcutaneous injection in the superior external quadrant of the buttock or in the upper outer thigh.
Initially 60mg every 28 days, adjusted according to response; maximum dose 120mg every 28 days by deep subcutaneous injection in the superior external quadrant of the buttock or in the upper outer thigh.
Initially 60mg every 28 days, adjusted according to response; maximum dose 120mg every 28 days by deep subcutaneous injection in the superior external quadrant of the buttock or in the upper outer thigh.
Prescribing Notes:
- Pasireotide and Pegvisomant are approved for use in patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.
- Treatment may cause diarrhoea due to exocrine pancreatic insufficiency.
- Somatostatin analogues for neuroendocrine tumours and acromegalic patients are appropriate for shared care arrangements to facilitate the seamless transfer of individual patient care from secondary care to general practice.
- The primary treatment of acromegaly is usually pituitary surgery. Management and treatment requires specialist involvement.
- For patients who receive a stable dose of Somatuline Autogel, and after appropriate training, the product may be administered either by the patient or by a trained person. In case of self-injection the injection should be given in the upper outer thigh.
- The decision regarding administration by the patient or a trained person should be taken by a healthcare professional.
History Notes
28/03/2024
Lanreotide product update, ERWG March 24.
21/02/2023
Addition of alternative long-acting octreotide formulation, ERWG Jan 2023
16/02/2022
East Region Formulary content agreed.